Randomized, Double-blind, Placebo-Controlled, Efficacy Study of a New Formulation of Phenylephrine HCL in the Common Cold
NCT ID: NCT03339726
Last Updated: 2019-06-04
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
193 participants
INTERVENTIONAL
2017-11-30
2018-04-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety Assessment of an Anti-Cold Preparation in the Symptomatic Treatment of Common Cold and Flu-Like Syndrome
NCT00940836
Efficacy and Safety of the Combination of Acetylcysteine, Paracetamol and Phenylephrine for the Treatment of Common Cold
NCT05070650
To Evaluate the Efficacy and Safety of 1146A Nasal Spray in Adult Participants With Symptoms of Common Cold
NCT03005067
Mucinex Exploratory Cold Study
NCT01046136
Phase 3 Clinical Trial to Evaluate Paracetamol /Fexofenadine /Phenylephrine in Flu and Cold Treatment
NCT05118672
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
New Formulation Phenylephrine HCl
New Formulation Phenylephrine HCl
2 doses of one tablet 12 hours apart
Marketed Phenylephrine HCl
Marketed Phenylephrine HCl
4 doses of one capsule 4 hours apart
Placebo
Placebo
4 doses of placebo capsule and tablet taken 4 hours apart
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
New Formulation Phenylephrine HCl
2 doses of one tablet 12 hours apart
Marketed Phenylephrine HCl
4 doses of one capsule 4 hours apart
Placebo
4 doses of placebo capsule and tablet taken 4 hours apart
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Exclusion Criteria
2. Any ear, nose, throat, or respiratory tract disease, other than the common cold, identified by signs and symptoms reported by the subject, or by medical history or medication history
3. Presence of asthma.
4. History of rhinitis medicamentosa, anatomical nasal obstruction or deformity, nasal reconstructive surgery, or chronic sleep apnea.
5. Fever of ≥ 101.0 °F (38.3 °C).
6. Heart disease, controlled or uncontrolled hypertension, thyroid disease, diabetes, glaucoma, prostatic hypertrophy, or presence of a disease, which in the opinion of the investigator, would preclude the use of phenylephrine.
7. Are currently taking, or have taken within two weeks of screening, a monoamine oxidase inhibitor (MAOI).
8. Have the need to use medications which may impact nasal symptomatology i.e. systemic, inhaled (oral or nasal) corticosteroids, and the following drugs with significant anticholinergic properties: tricyclic antidepressants, paroxetine, medicines used to treat overactive bladder, antipsychotic medication, skeletal muscle relaxants, antiparkinsonian medication, the anticonvulsants carbamazepine and oxcarbazepine, and dicycloverine (dicyclomine), dimenhydrinate, propantheline, atropine, hyoscyamine, belladonna, prochlorperazine and promethazine.
9. Have a bacterial sinus infection within 2 weeks prior to screening.
10. Use of systemic antibiotics within the past 7 days prior to screening.
11. Known or suspected alcohol or substance abuse (e.g., amphetamines, benzodiazepines, cocaine, marijuana, opiates).
12. Use of marijuana containing substances within the 10 days prior to screening and throughout the study.
13. Positive Urine Drug Screen.
14. Use of alcohol throughout the study.
15. History of smoking tobacco products or use of nicotine-containing substances within the previous three months as determined by subject's medical history or subject's verbal report.
16. Known sensitivity to the investigational product or any excipients of the drug product.
17. Before the first dose of study medicine, use of
1. oral or intranasal cold, cough, allergy, or analgesic/antipyretic medicines within approximately 12 hours;
2. menthol products, medicated lozenge, humidifier, nasal saline spray or throat spray within approximately 6 hours;
3. herbal/dietary supplements within approximately 12 hours.
18. Have difficulty swallowing tablets/capsules or are unable to swallow whole without crushing, chewing, splitting, or dissolving.
19. Subjects who were previously randomized and received the IP.
20. Significant unstable or uncontrolled medical condition that may interfere with a subject's participation in the study.
21. Other severe, acute or chronic, medical or psychiatric condition(s) or laboratory abnormality that may increase the risk associated with study participation or IP administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
22. Currently participating in another clinical trial or has done so in the past 30 days.
23. Subjects who are related to those persons involved directly or indirectly with the conduct of this study (i.e., principal investigator, sub-investigators, study coordinators, other site personnel, employees of Johnson \& Johnson (J\&J) subsidiaries, contractors of J\&J, and the families of each).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Johnson & Johnson Consumer Inc. (J&JCI)
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Steve Sacavage
Role: STUDY_DIRECTOR
Johnson and Johnson Consumer, Inc
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Medical Arts Health Research Group
Kelowna, British Columbia, Canada
Mission Hills Urgent Care Walk in Clinic
Mission, British Columbia, Canada
James Lai, MD, Inc
Vancouver, British Columbia, Canada
NEOMO Research
Greater Sudbury, Ontario, Canada
Dawson Road Family Medical Clinic
Guelph, Ontario, Canada
Sunningdale Health and Wellness Centre
London, Ontario, Canada
Bluewater Clinical Research Group, Inc.
Sarnia, Ontario, Canada
Canadian Phase Onward, Inc.
Toronto, Ontario, Canada
PrimeHealth Clinical Research
Toronto, Ontario, Canada
Diex Recherche
Sherbrooke, Quebec, Canada
Diex Recherche
Victoriaville, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CO-170302131230-URCT
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.